NV
Novartis Venture Fund
Novartis Venture Fund is a seed to Series E stage investment firm. It has made 133 investments. 45% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (6 deals in the last 12 months vs 12 prior). Average disclosed round size is $65.0M (across 163 rounds with reported amounts).
Portfolio
133
Fund Size
—
Top Stage
Series A
Last 12 Mo
6
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
214 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Kynexis | Series A | — | Aug 2026 |
 Flare Therapeutics | Series C | — | Jun 2026 |
 Sidewinder | Series B | $137M | Apr 2026 |
 EpiBiologics | Series B | — | Jan 2026 |
| Sidewinder | Series B | $137M | Jan 2026 |
| SSidewinder Therapeutics | Series B | $137M | Jan 2026 |
| PProtego Biopharma | Series B | $130M | Dec 2025 |
 Artios | Series D | $115M | Nov 2025 |
 NRG Therapeutics | Series B | $50M | Sep 2025 |
 SpliceBio | Series B | $135M | Jun 2025 |
 Fore Biotherapeutics | Series D | $38M | May 2025 |
 Granite Bio | Series A | $30M | Apr 2025 |
| Granite Bio | Series B | $70M | Apr 2025 |
 Atalanta Therapeutics | Series B | $75M | Jan 2025 |
 Alesta | Series A | — | Jan 2025 |
| PProtego Biopharma | Series B | $130M | Jan 2025 |
| FFore Bio | Series C | $57M | Jan 2025 |
 Alesta Therapeutics | Series A | — | Jan 2025 |
 Citryll | Series B | — | Dec 2024 |
 Cleerly | Series C | $106M | Dec 2024 |
 HYKU Biosciences | Seed | $64M | Nov 2024 |
| LLanova | Series C | $42M | Oct 2024 |
 LoQus23 | Series A | $43M | Oct 2024 |
 ONL Therapeutics | Unknown | $65M | Sep 2024 |
 Epsilogen Ltd | Series B | — | Sep 2024 |
Page 1 of 9
Top Co-Investors
OrbiMed28 shared
Novartis Pharma AG27 shared
Pfizer Ventures23 shared
Forbion21 shared
Sofinnova Partners20 shared
RA Capital Management20 shared
GV19 shared
New Enterprise Associates15 shared
Alexandria Venture Investments15 shared
Roche Venture Fund13 shared
EQT Life Sciences12 shared
Andera Partners11 shared
Versant Ventures11 shared
The Invus Group, LLC11 shared
Bristol Myers Squibb11 shared
Omega Funds11 shared
M Ventures11 shared
Eli Lilly and Company11 shared
Longwood Fund11 shared
Novo Capital10 shared
Last updated: 20 October 2026